Minerva Neurosciences, Inc. (NASDAQ:NERV) Short Interest Down 20.0% in December

Minerva Neurosciences, Inc. (NASDAQ:NERV) was the recipient of a significant decline in short interest during the month of December. As of December 15th, there was short interest totalling 7,600 shares, a decline of 20.0% from the November 30th total of 9,500 shares. Based on an average trading volume of 24,000 shares, the short-interest ratio is presently 0.3 days. Approximately 0.1% of the shares of the company are sold short.

Analyst Ratings Changes

A number of brokerages recently issued reports on NERV. StockNews.com initiated coverage on Minerva Neurosciences in a research report on Saturday. They issued a “sell” rating for the company. HC Wainwright reiterated a “neutral” rating and issued a $5.00 price objective on shares of Minerva Neurosciences in a research note on Wednesday, November 6th.

Minerva Neurosciences Stock Down 3.1 %

NASDAQ:NERV traded down $0.07 during trading hours on Tuesday, reaching $2.22. 26,096 shares of the company’s stock were exchanged, compared to its average volume of 50,371. Minerva Neurosciences has a 1-year low of $2.06 and a 1-year high of $13.49. The firm has a market capitalization of $15.52 million, a price-to-earnings ratio of -5.05 and a beta of 0.11. The company has a 50-day moving average of $2.27 and a 200 day moving average of $2.68.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.